ClinicalTrials.gg
CompletedNCT01025791Updated Feb 20, 2019Results posted

A Single Dose Study of MK-8266 (MK-8266-001)

A Phase 1 interventional study of MK-8266 0.1 mg and MK-8266 1.0 mg in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Hypertension by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hypertension · Merck & Co., Inc.

Enrollment
28th of 32
25 · median 84
Started
2009
with 3 others
Phase 1
17 of 33
none open now
Registered
15th of 33
by date

Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 28th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2009, is one of 17 in phase 1, and was the 15th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 33 studies in Hypertension by Merck & Co., Inc is open now. The open studies under Hypertension, anywhere →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Hypertension by Merck & Co., Inc as a file.
02

Study summary

A three panel study, to determine if MK-8266 given as a single dose is sufficiently safe and well tolerated. Panel A and B will consist of healthy young males and Panel C will consist of subjects with mild to moderate hypertension. The primary hypotheses for the study are that MK-8266 given as single doses is sufficiently safe and well tolerated to permit continued clinical investigation in healthy young male volunteers and male participants with mild-to-moderate hypertension and that in males with mild to moderate hypertension, at a single oral dose of MK-8266 that is sufficiently safe and well-tolerated, postdose mean time-weighted average across 24 hours of aortic augmentation index (TWA0-12hrs AIx) is reduced compared to placebo. A mean decrease of ≥ 5 percentage points is considered clinically meaningful.

Read the detailed description

Three panels, each consisting of either 8 or 9 participants (8 healthy young males in Panel A and Panel B; and 9 participants with mild to moderate hypertension in Panel C) will be randomized to receive either MK-8266 or matching placebo in either a 6:2 ratio (Panel A and Panel B) or 6:3 ratio (Panel C), respectively, in up to 5 treatment (1 to 5) periods in Panel A and up to 4 treatment (1 to 4) periods in Panel B and Panel C. In all panels, doses will be escalated in a rising, fixed sequence. Some participants took study drug after fasting and some with food.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Panel A and B Participant is a healthy male between 18 to 45 years of age. For Panel C Participant is a male with essential hypertension between 18 to 55 years of age
  • A non-smoker

Exclusion criteria

Exclusion Criteria:

  • Has a history of stroke, chronic seizure or major neurological disorder
  • Has a disability that can interfere with rising from a sitting position to the standing position
  • Has a personal of family history of bleeding or clotting disorders
  • Has a history of cancer
  • Is unable to refrain from or anticipates the use of any prescription or nonprescription drug during the study
  • Consumes excessive amounts of caffeine or alcohol
  • Has had major surgery, donated blood or participated in another study in the past 4 weeks
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Panel A, Healthy Male Participants, Sequence 1

    MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel A, Healthy Male Participants, Sequence 2

    MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel A, Healthy Male Participants, Sequence 3

    MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel A, Healthy Male Participants, Sequence 4

    MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel B, Healthy Male Participants, Sequence 1

    MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel B, Healthy Male Participants, Sequence 2

    MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel B, Healthy Male Participants, Sequence 3

    MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg

  • Experimental
    Panel B, Healthy Male Participants, Sequence 4

    MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel C, Mild/Moderate Hypertension, Sequence 1

    Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg

  • Experimental
    Panel C, Mild/Moderate Hypertension, Sequence 2

    Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel C, Mild/Moderate Hypertension, Sequence 3

    Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel C, Mild/Moderate Hypertension, Sequence 4

    Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

  • Experimental
    Panel C, Mild/Moderate Hypertension, Sequence 5

    Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg

  • Placebo comparator
    Panel C, Mild/Moderate Hypertension, Sequence 6

    Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na

    Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo

Interventions

  • Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

    Also known as: MK-8266

  • MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

  • DrugPlacebo

    Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced One or More Adverse Events

    An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.

    Time frame: Up to 14 days after administration of last dose of study drug in each study period (Up to 43 Days)

  2. Number of Participants Who Discontinued Study Drug Due to an AE

    An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.

    Time frame: Up to 43 days

  3. Aortic Augmentation Index - Time-Weighted Average 0-24 Hours

    Central ascending aortic blood pressure augmentation index (AIx) is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. AIx can be measured non-invasively by radial tonometry using aplanation tonometry of radial artery with the SphygmoCor Pulse Wave Analysis System Guide (SphygmoCor system). AIx was performed at prestudy to ensure an adequate waveform can be obtained. At each time point, a minimum of 2 AIx were completed in an attempt to obtain 2 acceptable quality assessments. A time weighted average was calculated. AIx was adjusted for heart rate. A decrease in the AIx of ≥5 percentage is considered clinically meaningful. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period. The 12-hour measurement was not collected (per protocol) in all periods of Panels A and B.

    Time frame: Predose, 1.5, 3, 12, and 24 hours postdose

  4. MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-inf\] is a measure of the mean concentration levels of drug in the plasma after the dose. AUC\[0-inf\] was not collected, analyzed or summarized for participants receiving placebo.

    Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose

  5. MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. For Panel A 1.0/0.8 mg MK-8266, the second dose was not well characterized due to limited sampling. Observed exposure likely underestimates the true exposure. Cmax was not collected, analyzed or summarized for participants receiving placebo.

    Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose

  6. MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Tmax was not collected, analyzed or summarized for participants receiving placebo.

    Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose

  7. MK-8266 PK Parameter Apparent t1/2

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Harmonic means +/- Pseudo standard deviations are displayed. t1/2 was not collected, analyzed or summarized for participants receiving placebo.

    Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose

Secondary outcomes

  1. Effect of Food on MK-8266 PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24hr) Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-24 hours\] is a measure of the mean concentration levels of drug in the plasma after the dose. The Fed Group was administered a high fat meal.

    Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 postdose

  2. Effect of Food on MK-8266 PK Parameter Cmax Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants

    PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. The Fed Group was administered a high fat meal.

    Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose

  3. Time-Weighted Average of Heart Rate (0-12 Hours)

    HR was measured with a validated automatic measuring device. Time weighted average was obtained as follows: For all HR values obtained over the 12-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.

    Time frame: Up to 12 hours

07

Results

Posted Feb 20, 2019

Participant flow

Participants were recruited at 2 clinical study sites in Germany and in Belgium.

Period 1
Participant flow — Period 1
MilestonePanel A, Healthy Male Participants, Sequence 1Panel A, Healthy Male Participants, Sequence 2Panel A, Healthy Male Participants, Sequence 3Panel A, Healthy Male Participants, Sequence 4Panel B, Healthy Male Participants, Sequence 1Panel B, Healthy Male Participants, Sequence 2Panel B, Healthy Male Participants, Sequence 3Panel B, Healthy Male Participants, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 1Panel C, Mild/Moderate Hypertension, Sequence 2Panel C, Mild/Moderate Hypertension, Sequence 3Panel C, Mild/Moderate Hypertension, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 5Panel C, Mild/Moderate Hypertension, Sequence 6
Started22222222212121
Completed22222222212121
Not completed00000000000000
Period 2
Participant flow — Period 2
MilestonePanel A, Healthy Male Participants, Sequence 1Panel A, Healthy Male Participants, Sequence 2Panel A, Healthy Male Participants, Sequence 3Panel A, Healthy Male Participants, Sequence 4Panel B, Healthy Male Participants, Sequence 1Panel B, Healthy Male Participants, Sequence 2Panel B, Healthy Male Participants, Sequence 3Panel B, Healthy Male Participants, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 1Panel C, Mild/Moderate Hypertension, Sequence 2Panel C, Mild/Moderate Hypertension, Sequence 3Panel C, Mild/Moderate Hypertension, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 5Panel C, Mild/Moderate Hypertension, Sequence 6
Started22222222212121
Completed22222222212121
Not completed00000000000000
Period 3
Participant flow — Period 3
MilestonePanel A, Healthy Male Participants, Sequence 1Panel A, Healthy Male Participants, Sequence 2Panel A, Healthy Male Participants, Sequence 3Panel A, Healthy Male Participants, Sequence 4Panel B, Healthy Male Participants, Sequence 1Panel B, Healthy Male Participants, Sequence 2Panel B, Healthy Male Participants, Sequence 3Panel B, Healthy Male Participants, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 1Panel C, Mild/Moderate Hypertension, Sequence 2Panel C, Mild/Moderate Hypertension, Sequence 3Panel C, Mild/Moderate Hypertension, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 5Panel C, Mild/Moderate Hypertension, Sequence 6
Started22222222212121
Completed22222222212121
Not completed00000000000000
Period 4
Participant flow — Period 4
MilestonePanel A, Healthy Male Participants, Sequence 1Panel A, Healthy Male Participants, Sequence 2Panel A, Healthy Male Participants, Sequence 3Panel A, Healthy Male Participants, Sequence 4Panel B, Healthy Male Participants, Sequence 1Panel B, Healthy Male Participants, Sequence 2Panel B, Healthy Male Participants, Sequence 3Panel B, Healthy Male Participants, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 1Panel C, Mild/Moderate Hypertension, Sequence 2Panel C, Mild/Moderate Hypertension, Sequence 3Panel C, Mild/Moderate Hypertension, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 5Panel C, Mild/Moderate Hypertension, Sequence 6
Started22222222212121
Completed22222222212121
Not completed00000000000000
Period 5
Participant flow — Period 5
MilestonePanel A, Healthy Male Participants, Sequence 1Panel A, Healthy Male Participants, Sequence 2Panel A, Healthy Male Participants, Sequence 3Panel A, Healthy Male Participants, Sequence 4Panel B, Healthy Male Participants, Sequence 1Panel B, Healthy Male Participants, Sequence 2Panel B, Healthy Male Participants, Sequence 3Panel B, Healthy Male Participants, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 1Panel C, Mild/Moderate Hypertension, Sequence 2Panel C, Mild/Moderate Hypertension, Sequence 3Panel C, Mild/Moderate Hypertension, Sequence 4Panel C, Mild/Moderate Hypertension, Sequence 5Panel C, Mild/Moderate Hypertension, Sequence 6
Started22220000000000
Completed22220000000000
Not completed00000000000000

Outcome measures

PrimaryNumber of Participants Who Experienced One or More Adverse Events

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.

Time frame:
Up to 14 days after administration of last dose of study drug in each study period (Up to 43 Days)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Adverse Events
ParticipantsPanel A MK-8266 0.1 mg (Healthy Males)Panel A MK-8266 0.2 mg (Healthy Males)Panel A MK-8266 0.5 mg (Healthy Males)Panel A MK-8266 1.0 mg (Healthy Males)Panel A MK-8266 1.0/0.8 mg (Healthy Males)Panel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 1.2 mg (Healthy Males)Panel B MK-8266 1.2/0.6 mg (Healthy Males)Panel B MK-8266 0.4 mg Fed (Healthy Males)Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)Pooled Placebo (Panels A, B, C)
Number of Participants Who Experienced One or More Adverse Events235231432346310
PrimaryNumber of Participants Who Discontinued Study Drug Due to an AE

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.

Time frame:
Up to 43 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Drug Due to an AE
ParticipantsPanel A MK-8266 0.1 mg (Healthy Males)Panel A MK-8266 0.2 mg (Healthy Males)Panel A MK-8266 0.5 mg (Healthy Males)Panel A MK-8266 1.0 mg (Healthy Males)Panel A MK-8266 1.0/0.8 mg (Healthy Males)Panel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 1.2 mg (Healthy Males)Panel B MK-8266 1.2/0.6 mg (Healthy Males)Panel B MK-8266 0.4 mg Fed (Healthy Males)Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)Pooled Placebo (Panels A, B, C)
Number of Participants Who Discontinued Study Drug Due to an AE00000000000000
PrimaryAortic Augmentation Index - Time-Weighted Average 0-24 Hours

Central ascending aortic blood pressure augmentation index (AIx) is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. AIx can be measured non-invasively by radial tonometry using aplanation tonometry of radial artery with the SphygmoCor Pulse Wave Analysis System Guide (SphygmoCor system). AIx was performed at prestudy to ensure an adequate waveform can be obtained. At each time point, a minimum of 2 AIx were completed in an attempt to obtain 2 acceptable quality assessments. A time weighted average was calculated. AIx was adjusted for heart rate. A decrease in the AIx of ≥5 percentage is considered clinically meaningful. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period. The 12-hour measurement was not collected (per protocol) in all periods of Panels A and B.

Time frame:
Predose, 1.5, 3, 12, and 24 hours postdose
Reported as:
Least squares mean · Percentage of central pulse pressure
Aortic Augmentation Index - Time-Weighted Average 0-24 Hours
Percentage of central pulse pressurePanel A MK-8266 0.1 mg (Healthy Males)Panel A MK-8266 0.2 mg (Healthy Males)Panel A MK-8266 0.5 mg (Healthy Males)Panel A MK-8266 1.0 mg (Healthy Males)Panel A MK-8266 1.0/0.8 mg (Healthy Males)Panel A PlaceboPooled Panel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 1.2 mg (Healthy Males)Panel B MK-8266 1.2/0.6 mg (Healthy Males)Panel B PlaceboPanel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod.Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)Panel C Placebo
Aortic Augmentation Index - Time-Weighted Average 0-24 Hours-8.79 ± 9.66-2.96 ± 9.15-1.73 ± 4.49-7.42 ± 3.85-5.70 ± 7.57-1.73 ± 7.36-13.1 ± 8.71-14.1 ± 7.49-16.7 ± 5.21-15.3 ± 2.688.43 ± 4.9811.29 ± 6.607.78 ± 11.108.74 ± 3.9017.74 ± 6.75
Statistical analysis
  • Panel A MK-8266 0.1 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = 0.003 · 0.1 mg vs. placebo: -7.06 · 90% CI -11.1 to -3.00
  • Panel A MK-8266 0.2 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = 0.310 · 0.2 mg vs. placebo: -1.23 · 90% CI -5.42 to 2.96
  • Panel A MK-8266 0.5 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = 0.498 · 0.5 mg vs. placebo: 0.01 · 90% CI -4.05 to 4.06
  • Panel A MK-8266 1.0 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = 0.012 · 1 mg vs. placebo: -5.69 · 90% CI -9.74 to -1.63
  • Panel A MK-8266 1.0/0.8 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = 0.059 · 1 mg + 0.8 mg vs. placebo: -3.97 · 90% CI -8.16 to 0.22
  • Pooled Panel B MK-8266 0.4 mg (Healthy Males) vs Panel B Placebo · ANOVA · p = 0.191 · 0.4 mg vs. placebo: 2.22 · 90% CI -2.09 to 6.54
  • Panel B MK-8266 1.2 mg (Healthy Males) vs Panel B Placebo · ANOVA · p = 0.333 · 1.2 mg vs. placebo: 1.24 · 90% CI -3.67 to 6.15
  • Panel B MK-8266 1.2/0.6 mg (Healthy Males) vs Panel B Placebo · ANOVA · p = 0.314 · 1.2 mg + 0.6 mg vs. placebo: -1.43 · 90% CI -6.50 to 3.63
  • Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension) vs Panel C Placebo · ANOVA · p = 0.001 · 1 mg + 0.8 mg vs. placebo: -9.31 · 90% CI -14.2 to -4.37
  • Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension) vs Panel C Placebo · ANOVA · p = 0.017 · 1.2 mg + 1.0 mg vs. placebo: -6.45 · 90% CI -11.4 to -1.51
  • Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. vs Panel C Placebo · ANOVA · p = 0.001 · 1.0 mg + 0.6 mg + 0.6 mg vs. placebo: -9.96 · 90% CI -14.9 to -5.02
  • Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) vs Panel C Placebo · ANOVA · p = 0.002 · 1 mg + 1 mg + 0.6 mg vs. placebo: -9.00 · 95% CI -13.8 to -4.17
PrimaryMK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-inf\] is a measure of the mean concentration levels of drug in the plasma after the dose. AUC\[0-inf\] was not collected, analyzed or summarized for participants receiving placebo.

Time frame:
Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
Reported as:
Mean · mg/mL*hr
MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
mg/mL*hrPanel A MK-8266 0.1 mg (Healthy Males)Panel A MK-8266 0.2 mg (Healthy Males)Panel A MK-8266 0.5 mg (Healthy Males)Panel A MK-8266 1.0 mg (Healthy Males)Panel A MK-8266 1.0/0.8 mg (Healthy Males)Panel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 1.2 mg (Healthy Males)Panel B MK-8266 1.2/0.6 mg (Healthy Males)Panel B MK-8266 0.4 mg Fed (Healthy Males)Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension)Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)
MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])———264 ± 64.4441 ± 105—216 ± 55.95350 ± 49.5———528 ± 151623 ± 350
PrimaryMK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. For Panel A 1.0/0.8 mg MK-8266, the second dose was not well characterized due to limited sampling. Observed exposure likely underestimates the true exposure. Cmax was not collected, analyzed or summarized for participants receiving placebo.

Time frame:
Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
Reported as:
Mean · nM
MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)
nMPanel A MK-8266 0.1 mg (Healthy Males)Panel A MK-8266 0.2 mg (Healthy Males)Panel A MK-8266 0.5 mg (Healthy Males)Panel A MK-8266 1.0 mg (Healthy Males)Panel A MK-8266 1.0/0.8 mg (Healthy Males)Panel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 1.2 mg (Healthy Males)Panel B MK-8266 1.2/0.6 mg (Healthy Males)Panel B MK-8266 0.4 mg Fed (Healthy Males)Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension)Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)
MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)2.28 ± 0.2914.33 ± 0.45411.4 ± 0.81922.2 ± 3.4020.5 ± 2.587.46 ± 1.4119.5 ± 5.1421.3 ± 4.167.71 ± 2.6419.1 ± 3.7722.1 ± 3.0621.7 ± 3.8022.4 ± 3.59
PrimaryMK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Tmax was not collected, analyzed or summarized for participants receiving placebo.

Time frame:
Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
Reported as:
Median · Hours
MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)
HoursPanel A MK-8266 0.1 mg (Healthy Males)Panel A MK-8266 0.2 mg (Healthy Males)Panel A MK-8266 0.5 mg (Healthy Males)Panel A MK-8266 1.0 mg (Healthy Males)Panel A MK-8266 1.0/0.8 mg (Healthy Males)Panel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 1.2 mg (Healthy Males)Panel B MK-8266 1.2/0.6 mg (Healthy Males)Panel B MK-8266 0.4 mg Fed (Healthy Males)Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension)Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)
MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)2.5 (1.5 to 4.0)4.0 (3.0 to 4.0)3.5 (2.0 to 4.0)4.0 (3.0 to 4.0)3.5 (2.0 to 8.0)3.0 (2.0 to 4.0)4.0 (2.0 to 6.0)3.0 (2.0 to 4.0)1.5 (1.5 to 6.0)3.0 (2.0 to 10.0)5.0 (3.0 to 10.0)6.5 (2.0 to 15.0)9.0 (3.0 to 15.0)
PrimaryMK-8266 PK Parameter Apparent t1/2

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Harmonic means +/- Pseudo standard deviations are displayed. t1/2 was not collected, analyzed or summarized for participants receiving placebo.

Time frame:
Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
Reported as:
Mean · Hours
MK-8266 PK Parameter Apparent t1/2
HoursPanel A MK-8266 0.1 mg (Healthy Males)Panel A MK-8266 0.2 mg (Healthy Males)Panel A MK-8266 0.5 mg (Healthy Males)Panel A MK-8266 1.0 mg (Healthy Males)Panel A MK-8266 1.0/0.8 mg (Healthy Males)Panel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 1.2 mg (Healthy Males)Panel B MK-8266 1.2/0.6 mg (Healthy Males)Panel B MK-8266 0.4 mg Fed (Healthy Males)Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension)Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)
MK-8266 PK Parameter Apparent t1/2———13.6 ± 2.611.7 ± 2.2—9.2 ± 3.512.0 ± 3.0———10.4 ± 2.212.8 ± 4.8
SecondaryEffect of Food on MK-8266 PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24hr) Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-24 hours\] is a measure of the mean concentration levels of drug in the plasma after the dose. The Fed Group was administered a high fat meal.

Time frame:
Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 postdose
Reported as:
Geometric least squares mean · nM·hr
Effect of Food on MK-8266 PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24hr) Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants
nM·hrPanel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 0.4 mg Fed (Healthy Males)
Effect of Food on MK-8266 PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24hr) Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants59.6 (38.9 to 91.2)52.9 (34.6 to 81.0)
Statistical analysis
  • Panel B MK-8266 0.4 mg (Healthy Males) vs Panel B MK-8266 0.4 mg Fed (Healthy Males) · Gmr (fed/fasted): 0.89 · 95% CI 0.86 to 0.92
SecondaryEffect of Food on MK-8266 PK Parameter Cmax Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants

PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. The Fed Group was administered a high fat meal.

Time frame:
Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
Reported as:
Geometric least squares mean · nM
Effect of Food on MK-8266 PK Parameter Cmax Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants
nMPanel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 0.4 mg Fed (Healthy Males)
Effect of Food on MK-8266 PK Parameter Cmax Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants7.5 (5.2 to 11.0)7.3 (5.0 to 10.6)
Statistical analysis
  • Panel B MK-8266 0.4 mg (Healthy Males) vs Panel B MK-8266 0.4 mg Fed (Healthy Males) · Gmr (fed/fasted): 0.97 · 95% CI 0.79 to 1.19
SecondaryTime-Weighted Average of Heart Rate (0-12 Hours)

HR was measured with a validated automatic measuring device. Time weighted average was obtained as follows: For all HR values obtained over the 12-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.

Time frame:
Up to 12 hours
Reported as:
Least squares mean · Beats per Minute
Time-Weighted Average of Heart Rate (0-12 Hours)
Beats per MinutePanel A MK-8266 0.1 mg (Healthy Males)Panel A MK-8266 0.2 mg (Healthy Males)Panel A MK-8266 0.5 mg (Healthy Males)Panel A MK-8266 1.0 mg (Healthy Males)Panel A MK-8266 1.0/0.8 mg (Healthy Males)Panel A PlaceboPooled Panel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 1.2 mg (Healthy Males)Panel B MK-8266 1.2/0.6 mg (Healthy Males)Panel B PlaceboPanel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod.Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)Panel C Placebo
Time-Weighted Average of Heart Rate (0-12 Hours)58.79 ± 6.7161.65 ± 3.0656.36 ± 4.8666.40 ± 7.9063.71 ± 3.1759.32 ± 6.2857.38 ± 5.9261.07 ± 5.0459.92 ± 10.2356.53 ± 6.6669.82 ± 8.0966.40 ± 9.8264.14 ± 7.4064.90 ± 8.3360.66 ± 8.07
Statistical analysis
  • Panel A MK-8266 0.1 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = 0.396 · 0.1 mg vs placebo: -0.53 · 90% CI -3.92 to 2.86
  • Panel A MK-8266 0.2 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = 0.1329 · 0.2 mg vs. placebo: 2.33 · 90% CI -1.17 to 5.83
  • Panel A MK-8266 0.5 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = 0.0741 · 0.5mg vs. placebo: -2.96 · 90% CI -6.35 to 0.43
  • Panel A MK-8266 1.0 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = <0.001 · 1 mg vs. placebo: 7.08 · 90% CI 3.69 to 10.47
  • Panel A MK-8266 1.0/0.8 mg (Healthy Males) vs Panel A Placebo · ANOVA · p = 0.0211 · 1 mg + 0.8 mg vs. placebo: 4.39 · 90% CI 0.89 to 7.09
  • Pooled Panel B MK-8266 0.4 mg (Healthy Males) vs Panel B Placebo · ANOVA · p = 0.399 · 0.4 mg vs. placebo: 0.85 · 90% CI -4.79 to 6.48
  • Panel B MK-8266 1.2 mg (Healthy Males) vs Panel B Placebo · ANOVA · p = 0.100 · 1.2 mg vs. placebo: 4.54 · 90% CI -1.94 to 11.02
  • Panel B MK-8266 1.2/0.6 mg (Healthy Males) vs Panel B Placebo · ANOVA · p = 0.195 · 1.2 mg + 0.6 mg vs. placebo: 3.38 · 90% CI -3.29 to 10.06
  • Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension) vs Panel C Placebo · ANOVA · p = 0.022 · 1.0 mg + 0.8 mg vs. placebo: 9.16 · 90% CI 1.74 to 16.58
  • Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension) vs Panel C Placebo · ANOVA · p = 0.098 · 1.2 mg + 1.0 mg vs. placebo: 5.74 · 90% CI -1.68 to 13.16
  • Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. vs Panel C Placebo · ANOVA · p = 0.214 · 1 mg + 0.6 mg + 0.6 mg vs. placebo: 3.48 · 90% CI -3.94 to 10.90
  • Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) vs Panel C Placebo · ANOVA · p = 0.163 · 1 mg + 1 mg + 0.6 mg vs. placebo: 4.24 · 95% CI -3.03 to 11.52

Adverse events

Collected over Up to 14 days after administration of the last dose of study drug (Up to 43 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A MK-8266 0.1 mg (Healthy Males)0/6 (0%)0/6 (0%)2/6 (33.3%)
Panel A MK-8266 0.2 mg (Healthy Males)0/6 (0%)0/6 (0%)3/6 (50%)
Panel A MK-8266 0.5 mg (Healthy Males)0/6 (0%)0/6 (0%)5/6 (83.3%)
Panel A MK-8266 1.0 mg (Healthy Males)0/6 (0%)0/6 (0%)2/6 (33.3%)
Panel A MK-8266 1.0/0.8 mg (Healthy Males)0/6 (0%)0/6 (0%)3/6 (50%)
Panel B MK-8266 0.4 mg (Healthy Males)0/6 (0%)0/6 (0%)1/6 (16.7%)
Panel B MK-8266 1.2 mg (Healthy Males)0/6 (0%)0/6 (0%)4/6 (66.7%)
Panel B MK-8266 1.2/0.6 mg (Healthy Males)0/6 (0%)0/6 (0%)3/6 (50%)
Panel B MK-8266 0.4 mg Fed (Healthy Males)0/6 (0%)0/6 (0%)2/6 (33.3%)
Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)0/6 (0%)0/6 (0%)3/6 (50%)
Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)0/6 (0%)0/6 (0%)4/6 (66.7%)
Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)0/6 (0%)0/6 (0%)6/6 (100%)
Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)0/6 (0%)0/6 (0%)3/6 (50%)
Pooled Placebo (Panels A, B, C)0/23 (0%)0/23 (0%)10/23 (43.5%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPanel A MK-8266 0.1 mg (Healthy Males)Panel A MK-8266 0.2 mg (Healthy Males)Panel A MK-8266 0.5 mg (Healthy Males)Panel A MK-8266 1.0 mg (Healthy Males)Panel A MK-8266 1.0/0.8 mg (Healthy Males)Panel B MK-8266 0.4 mg (Healthy Males)Panel B MK-8266 1.2 mg (Healthy Males)Panel B MK-8266 1.2/0.6 mg (Healthy Males)Panel B MK-8266 0.4 mg Fed (Healthy Males)Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension)Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension)Pooled Placebo (Panels A, B, C)
HeadacheNervous system disorders2/63/64/61/61/61/61/61/60/62/63/65/63/66/23
NauseaGastrointestinal disorders0/60/62/60/61/60/60/60/60/62/60/61/61/60/23
Abdominal discomfortGastrointestinal disorders0/60/60/60/60/60/60/60/60/60/61/60/60/60/23
Abdominal painGastrointestinal disorders0/60/60/60/61/60/60/60/60/60/60/60/60/60/23
Aphthous stomatitisGastrointestinal disorders0/60/60/60/60/60/60/60/60/60/61/60/60/60/23
DiarrhoeaGastrointestinal disorders0/60/60/60/61/60/60/60/60/60/60/60/60/60/23
DyspepsiaGastrointestinal disorders0/60/60/61/60/60/60/60/60/60/60/60/60/60/23
ToothacheGastrointestinal disorders0/60/60/60/60/60/60/60/61/60/60/60/60/60/23
VomitingGastrointestinal disorders0/60/60/60/60/60/60/60/60/61/60/61/61/60/23
NasopharyngitisInfections and infestations0/60/61/60/60/60/60/61/60/60/60/60/60/61/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panel A MK-8266 (Healthy Males)Panel B MK-8266 (Healthy Males)Panel C MK-8266 (Mild/Mod. Hypertension)Total
Mean34.3 ± 8.127.3 ± 5.447.3 ± 3.936.7 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Panel A MK-8266 (Healthy Males)Panel B MK-8266 (Healthy Males)Panel C MK-8266 (Mild/Mod. Hypertension)Total
Female0000
Male88925
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2009 to primary completion in May 2010, 5 months.

Results were first posted in Feb 2019, 8 years 9 months after primary completion.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 5 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2009
First posted
Dec 4, 2009
StartActual
Nov 18, 2009
Primary completionActual
May 14, 2010
CompletionActual
May 14, 2010
Results first posted
Feb 20, 2019
Last update
Feb 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01025791
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Nov 18, 2009
Primary completion
May 14, 2010
Completion
May 14, 2010
Results posted
Feb 20, 2019
Last update
Feb 20, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-8266

Start the discussion